Fig. 1From: Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamideNomogram for predicting 1- and 2-year survival in mCRPC treated with abiraterone acetate and/or enzalutamideBack to article page